Recent News

• 10.29.2026 - 2-Year Overall Survival Results From DAZALS: A Phase 2, Randomized Controlled Trial of Dazucorilant, a Selective Glucocorticoid Receptor Modulator, in Amyotrophic Lateral Sclerosis
• 10.27.2026 - Budget Impact of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer: A US Payer Perspective
• 10.27.2026 - Infusion Chair Time and Clinic Visits as Drivers of Healthcare Resource Utilization in Platinum-Resistant Ovarian Cancer
• 10.26.2026 - Pooled Safety Analysis of Relacorilant Plus Nab-paclitaxel in Patients With Platinum-resistant Ovarian Cancer Enrolled to ROSELLA and Study 552
• 10.26.2026 - Meta-analysis of Relacorilant Plus Nab-paclitaxel Efficacy in Patients With Platinum-resistant Ovarian Cancer (PROC) Enrolled to ROSELLA and Study 552
• 10.16.2026 - Relacorilant Provides Significant Benefit Across Cardiometabolic Outcomes in Global Statistical Tests of the Placebo-controlled, Randomized-withdrawal GRACE Trial in Cushing Syndrome
• 10.08.2026 - Characteristics Associated With Endogenous Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disorders: Analyses From the MOMENTUM Study
• 08.01.2026 - Prevalence of Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disease
• 06.22.2026 - Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension Stratified by Kidney Function: Results From the MOMENTUM Study
• 06.18.2026 - Efficacy and Safety of Relacorilant + Nab-paclitaxel in Patients Aged ≥65 Years With Platinum-resistant Ovarian Cancer (PROC) in the Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10)

Recent Filings

• 10.27.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.05.2026 - 3 Initial statement of beneficial ownership of securities
• 10.01.2026 - 144 Report of proposed sale of securities
• 09.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.23.2026 - 8-K Current report